GlassScriptPhysician profile
Leeina E Hoff
NPI 1578910923
$2,827.30
in general payments reported to CMS, 2019-2025
40 companies · $2,827 in 2025
The $2,827 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,733 · Education: $93.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.32 |
| Education | $93.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $352.18 | 2025 | Imfinzi, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $316.02 | 2025 | Rybrevant, Carvykti, Akeega |
| Daiichi Sankyo INC. | $224.90 | 2025 | Injectafer, Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $173.27 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Glaxosmithkline, LLC. | $150.07 | 2025 | Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $135.70 | 2025 | Opdivo |
| Pfizer INC. | $109.71 | 2025 | |
| Beone Medicines USA, INC. | $102.19 | 2025 | Tevimbra, Brukinsa |
| Genzyme Corporation | $101.67 | 2025 | |
| Array Biopharma INC | $85.75 | 2025 | Mektovi, Braftovi, Tukysa |
| Seagen INC. | $77.99 | 2025 | |
| Deciphera Pharmaceuticals INC. | $71.73 | 2025 | Romvimza, Qinlock |
| Genentech USA, INC. | $66.47 | 2025 | Tecentriq, Lunsumio |
| Astellas Pharma US INC | $60.19 | 2025 | Xtandi, Padcev |
| Kyowa Kirin, INC. | $58.90 | 2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leeina Hoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.